Neubauer 1984.

Methods	Study design: parallel RCT Duration of study: July 1980 to September 1981 Duration of follow‐up: 18 months
Participants	Country: Germany Setting: single centre Inclusion criteria: kidney transplant recipients Number: 38 (numbers per group not reported) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: SCr > 0.16 mmol/L, hypercalcaemia or systemic disease
Interventions	Treatment group 1,25 dihydroxyvitamin D3 (oral): 0.25 µg/d Control group Placebo Co‐interventions Not reported
Outcomes	SCr BMD by DEXA at radius
Notes	Funding source: Hoffman La Roche provided medication Trial registration: not applicable as published before end of 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	High risk	10/38 participants did not complete study
Selective reporting (reporting bias)	High risk	Patient‐centred outcomes not reported in sufficient detail to include in meta‐analysis
Other bias	Unclear risk	Insufficient information to permit judgement